ECS Botanics Holdings Ltd (ASX: ECS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
ECS Botanics Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ECS Botanics Holdings Ltd (ASX: ECS)
Latest News
Cannabis Shares
Why the ECS Botanics (ASX:ECS) share price is smoking the ASX today
Share Market News
ECS Botanics (ASX:ECS) share price slumps 10% on capital raising efforts
Share Market News
Why the ECS Botanics (ASX:ECS) share price is moving higher today
Share Market News
ECS Botanics (ASX:ECS) share price edges lower despite positive update
Share Market News
Why the ECS (ASX:ECS) share price is soaring 16% higher today
ECS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About ECS Botanics Holdings Ltd
ECS Botanics Holdings Ltd an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, ECS provides of quality, affordable medicinal cannabis supplying both local and overseas markets.
ECS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
12 Dec 2024 | $0.02 | $0.00 | 0.00% | 267,454 | $0.02 | $0.02 | $0.02 |
11 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,300 | $0.02 | $0.02 | $0.02 |
10 Dec 2024 | $0.02 | $0.00 | 0.00% | 58,780 | $0.02 | $0.02 | $0.02 |
09 Dec 2024 | $0.02 | $0.00 | 0.00% | 702,114 | $0.02 | $0.02 | $0.02 |
06 Dec 2024 | $0.02 | $0.00 | 0.00% | 630,006 | $0.02 | $0.02 | $0.02 |
05 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,247,043 | $0.02 | $0.02 | $0.02 |
04 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,871,407 | $0.02 | $0.02 | $0.02 |
03 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,273,076 | $0.02 | $0.02 | $0.02 |
02 Dec 2024 | $0.02 | $0.00 | 0.00% | 1,850,403 | $0.02 | $0.02 | $0.02 |
29 Nov 2024 | $0.02 | $0.00 | 0.00% | 619,395 | $0.02 | $0.02 | $0.02 |
28 Nov 2024 | $0.02 | $0.00 | 0.00% | 601,814 | $0.02 | $0.02 | $0.02 |
27 Nov 2024 | $0.02 | $0.00 | 0.00% | 23,500 | $0.02 | $0.02 | $0.02 |
26 Nov 2024 | $0.02 | $0.00 | 0.00% | 647,716 | $0.02 | $0.02 | $0.02 |
25 Nov 2024 | $0.02 | $0.00 | 0.00% | 2,530,784 | $0.02 | $0.02 | $0.02 |
22 Nov 2024 | $0.02 | $0.00 | 0.00% | 270,588 | $0.02 | $0.02 | $0.02 |
21 Nov 2024 | $0.02 | $0.00 | 0.00% | 1,323,311 | $0.02 | $0.02 | $0.02 |
20 Nov 2024 | $0.02 | $0.00 | 0.00% | 140,318 | $0.02 | $0.02 | $0.02 |
19 Nov 2024 | $0.02 | $0.00 | 0.00% | 241,156 | $0.02 | $0.02 | $0.02 |
18 Nov 2024 | $0.02 | $0.00 | 0.00% | 242,689 | $0.02 | $0.02 | $0.02 |
15 Nov 2024 | $0.02 | $0.00 | 0.00% | 3,651,833 | $0.02 | $0.02 | $0.02 |
14 Nov 2024 | $0.02 | $0.00 | 0.00% | 720,971 | $0.02 | $0.02 | $0.02 |
13 Nov 2024 | $0.02 | $0.00 | 0.00% | 3,362,619 | $0.02 | $0.02 | $0.02 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 May 2024 | Jeremy King | Buy | 3,333,333 | $49,999 |
Off-market trade.
|
02 May 2024 | Alexander (Alex) Keach | Sell | 50,000,000 | $750,000 |
Off-market trade.
|
02 May 2024 | Nan-Maree Schoerie | Buy | 6,666,667 | $100,000 |
Off-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Jeremy Philip King | Non-Executive DirectorNon-Executive Chairman | Jan 2017 |
Mr King has over 20 years' experience in domestic and international legal, financial, and corporate matters. Mr. King is a director of a boutique corporate advisory and compliance business where he specialises in corporate and strategic advice and managing legal issues associated with clients. He spent several years in London where he worked with Allen and Overy LLP and Debevoise & Plimpton LLP and has experience, particularly in relation to cross border private equity, leveraged buy-out acquisitions and acting for banks, financial institutions, and corporate issuers in respect of debt and equity capital raisings. He regularly advises ASX listed companies on corporate and commercial matters.
|
Mr Michael Nitsche | Non-Executive Director | Mar 2019 |
Mr Nitsche is the founder and Executive Director of ARQ Capital, a boutique corporate advisory firm based in Perth, Western Australia. He has experience in equity capital markets, advising on deal structuring for IPO's, equity capital raisings, mergers, and acquisitions. From 2011 to 2014 Michael served as Institutional Advisor and Associate Director at two of Australia's stockbroking firms. Michael has held directorships that span public and private boards across multiple market sectors.
|
Ms Nan-Maree Schoerie | Managing Director | Mar 2021 |
Ms Schoerie has held Australian business leader positions of organisations such as GE, ThermoFisher and Ventia, having shown an ability to deliver bottom- and top-line growth across different geographies and industries. Nan's passion for delivering customer value and her determination to deliver outcomes resulted in customer retention rates whilst regularly securing annuity contracts, some valued at over $200m. As Managing Director Nan is responsible for managing the overall business, ensuring the safety and wellbeing of employees, building a performing Company culture, ensuring Customer satisfaction, and delivering on the Company's financial objectives. In addition, Nan works with the board to provide strategic guidance, and ensure good governance.
|
Dr Rachel Swift | Non-Executive Director | Oct 2024 |
Dr Swift With nearly 20 years experience across the healthcare sector, Dr Swift joins the ECS Board with a track record in driving transformative health initiatives and leading strategic change in complex environments. Dr Swift has held senior positions in companies at the forefront of health system management, public health, infectious diseases, digital health, and medical research, including a decade at The Boston Consulting Group where she focused on business strategy, healthcare innovation, and enhancing patient outcomes. Dr Swift serves on several boards, including the Innovation & Enterprise Advisory Board at the University of Melbourne School of Medicine, Dentistry, and Health Sciences. She also chairs the Finance Committee at GPEx, where she holds the position of Vice-Chair. In addition to her executive and board roles, Dr Swift has held academic appointments at the Universities of Oxford and Adelaide.
|
Mr Mauro Piccini | Company Secretary | Nov 2017 |
-
|
Xiao Dong (Arthur) Sun | Chief Financial Officer |
-
|
|
Mauro Piccini | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Harbour Capital Asset Management Pty Ltd | 71,000,000 | 5.51% |
Flowerday Holdings Pty Ltd | 70,666,667 | 5.48% |
Keach Securities And Investments Pty Ltd | 50,253,739 | 3.90% |
Schoerie Fides Pty Ltd | 42,000,000 | 3.26% |
Super Secret Pty Limited | 35,500,000 | 2.76% |
Mr Benjamin John Harington | 25,125,095 | 1.95% |
Windpac Pty Ltd | 22,727,300 | 1.76% |
10 Bolivianos Pty Ltd | 18,717,775 | 1.45% |
Taos Pty Ltd | 15,621,296 | 1.21% |
Arcus Callisto Pty Ltd | 14,166,666 | 1.10% |
Da & Dj Burt Pty Ltd | 13,425,643 | 1.04% |
C Y T Investment Pty Ltd | 12,000,000 | 0.93% |
Mr Alexander Beard | 11,363,700 | 0.88% |
Fordholm Consultants Pty Ltd | 10,000,000 | 0.78% |
Rubino Group Pty Ltd | 9,100,000 | 0.71% |
Mr John Philip Daniels | 8,573,323 | 0.67% |
Windpac Pty Ltd i | 8,073,333 | 0.63% |
Mr Haojie Li | 8,035,909 | 0.62% |
Mr Christopher Leon Laidely | 8,000,000 | 0.62% |
Sargood Super Pty Ltd | 7,600,000 | 0.59% |